#USA #Kessler Topaz #Radnor #ImmunityBio #IBRX

IBRX Securities Class Action Update

The world of securities trading can be complex and perilous, particularly when allegations of fraud surface. One such situation has arisen regarding ImmunityBio, Inc.

Key Details of the Class Action

The law firm Kessler Topaz Meltzer & Check, LLP is currently spearheading a securities fraud class action lawsuit against ImmunityBio. This lawsuit is on behalf of investors who acquired ImmunityBio securities over a specified period, from January 19, 2026, through March 24, 2026. This notable case, titled Douglas v. ImmunityBio, Inc., is filed in the United States District Court for the Central District of California.

Background on the Allegations

Investors are alerted to a pressing deadline - May 26, 2026 - which marks the last day to file for lead plaintiff status. The allegations in this class action primarily relate to significant misstatements and omissions made by the defendants regarding ImmunityBio's lead biologic product, Anktiva. The complaint highlights that the company misrepresented the product's capabilities, notably declaring it as a potential cancer vaccine—a statement questioned by medical authorities following critical scrutiny.

On March 24, 2026, the FDA issued a warning regarding the marketing claims made by ImmunityBio's Executive Chairman regarding Anktiva, stating that they were false or misleading. This revelation triggered a substantial drop in the company’s stock price, falling by over 21% in a single day.

The Process for Affected Investors

As an affected investor, you have several options ahead of you:

• - File for Lead Plaintiff Status: If you feel financially impacted by these allegations, consider becoming a lead plaintiff, which requires you to file by May 26, 2026.
• - Contact Legal Counsel: Those interested can reach out to Jonathan Naji, an attorney at Kessler Topaz. A free consultation is available, where you can discuss your legal rights and the implications of the lawsuit with no obligation.

Why You Should Act Now

The outcome of this class action could have significant consequences for affected IBRX investors, potentially paving the way for monetary recovery. Engaging with legal representation can also ensure that your voice is heard among other investors in class actions, which often only succeed with a unified front.

If you have invested in ImmunityBio, don't hesitate. Review your options and consult with legal experts to ascertain the best path forward. Remember, taking action can greatly influence the outcome of this legal situation.

For further information on how to participate, contact Kessler Topaz Meltzer & Check, LLP at their official website. In the game of securities trading, knowledge truly is power, and being informed could turn the tides in your favor.